Contact Information
Marcin Kortylewski, Ph.D.
  • Associate Professor, Department of Cancer Immunotherapeutics & Tumor Immunology

Professional Experience

  • 2015 - present, Associate Professor, Department of Cancer Immunotherapeutics & Tumor Immunology, Beckman Research Institute of City of Hope, Duarte, CA
  • 2010 - 2015, Assistant Professor, Department of Cancer Immunotherapeutics & Tumor Immunology, Beckman Research Institute of City of Hope, Duarte, CA
  • 2005 - 2009, Assistant Research Scientist, Department of Cancer Immunotherapeutics & Tumor Immunology, Beckman Research Institute of City of Hope, Duarte, CA
  • 2005, Research Scientist, Immunology Program, H. Lee Moffitt Cancer Center, Tampa, FL


  • 2002 - 2005, H. Lee Moffitt Cancer Center, Tampa, FL., Immunology Program, Post-doctoral Fellow
  • 1999 - 2002, RWTH Aachen, Germany, Department of Biochemistry, Post-doctoral Fellow
  • 1999, University School of Medical Sciences, Poznan, Poland, Molecular Biology, Ph.D.
  • 1996 - 1998, RWTH Aachen, Germany, Department of Biochemistry, Graduate Student, Faculty of Medicine
  • 1991 - 1996, Adam Mickiewicz University, Poznan, Poland, Biotechnology, M.S.


  • 2013, STOP Cancer, Alison Tovo-Dwyer Memorial Research Career Development Award
  • 2012, ThinkCure! Research Award
  • 2011, V Foundation Team Award
  • 2011, Margaret E. Early Medical Research Award
  • 2011, Research Excellence Award, City of Hope
  • 2008, “Methods and compositions for the treatment of cancer and other diseases” -- Inventors: H. Yu, M. Kortylewski, P. Swiderski, R. Jove, J. Rossi (pending).
  • 2006 - 2008, Research grant and competitive renewal from Harry J. Lloyd Charitable Trust, “Inhibiting Stat3 to enhance melanoma immunotherapies”, (H. Yu, PI and M. Kortylewski, co-PI).
  • 2005, “Methods for inhibiting STAT3 signaling in immune cells” -- Inventors: H. Yu, R. Jove, M. Kortylewski, D.M. Pardoll (pending).
  • 2004, Takeda Scholar-in-Training Award of the American Association of Cancer Research, 95th Annual Meeting of AACR
  • 2004, Keystone Symposia Travel Award “Jaks and Stats: Development to Disease”, Whistler, Canada
  • 1998 - 2000, Research grant, Polish State Committee for Scientific Research (M. Kortylewski, PI).
  • 1996 - 1999, Faculty Fellow, University School of Medical Sciences, Poznan, Poland
  • 1995 - 1996, Polish Ministry of Education Scholarship


  • 2012 - present, Oligonucleotide Therapeutics Society.
  • 2003 - present, American Association of Cancer Research


  • Zhang Q., Hossain D.M.S., Nechaev S., Kozlowska A., Zhang W., Liu Y., Kowolik C.M., Swiderski P., Rossi J.J., Forman S., Yu H., Kortylewski M. TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo. Blood, 2013.
  • Lee H., Deng J., Kujawski M., Yang C., Liu Y., Herrmann A., Kortylewski M., Horne D., Somlo G., Forman S., Jove R., Yu H. STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors. Nature Med., 2010.
  • Herrmann A., Kortylewski M.*, Kujawski M., Zhang C., Reckamp K., Armstrong B., Wang L., Kowolik C., Deng J., Figlin R., Yu H. Targeting Stat3 in the myeloid compartment drastically improves the in vivo antitumor functions of adoptively transferred T cells. Cancer Res., 70, 7455-7564. *corresponding author.
  • Kortylewski M., Swiderski P., Kujawski M., Herrmann A., Kowolik C., Xin H., Lee H., Rossi J., Jove R., Pardoll D.M. and Yu H. TLR agonist–Stat3 siRNA conjugates: cell-specific gene silencing and enhanced antitumor immune responses. Nature Biotechnol., 27, 925-932, 2009.
  • Kortylewski M., Xin H., Kujawski M., Lee H., Liu Y., Harris T., Drake C.G., Pardoll D.M. and Yu H. Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell, 15, 114-123, 2009.
  • Wang L., Yi T., Kortylewski M., Pardoll D.M., Zeng D. and Yu H. IL-17 can promote tumor growth through an IL-6/Stat3 signaling pathway. J. Exp. Med., 206, 1457-1464, 2009.
  • Kortylewski M.*, Kujawski M., Herrmann A., Xin H., Wang L., Yu H. Stat3 constrains the efficacies of TLR9 agonist-based immunotherapy. Cancer Res., 69, 2497-2505, 2009. *corresponding author.
  • Zhang L., Alizadeh D., Van Handel M., Kortylewski M., Yu H., Badie B. Stat3 inhibition activates tumor macrophages and abrogates glioma growth in mice. Glia, 57, 1458-1467, 2009.
  • Kortylewski M., Yu H. Role of Stat3 in suppressing anti-tumor immunity. Curr. Opin. Immunol., 20, 228-233, 2008.
  • Kujawski M.*, Kortylewski M.*, Lee H., Herrmann A., Yu H. Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J. Clin. Invest. 118, 3367-3377, 2008. *equally contributing authors.
  • Niu G., Briggs J., Deng J., Ma Y., Lee H., Kortylewski M., Kujawski M., Kay H., Cress D., Jove R., and Yu H. Signal transducer and activator of transcription 3 is required for hypoxia-inducible factor-1alpha RNA expression in both tumor cells and tumor-associated myeloid cells. Mol. Cancer Res. 6, 1099-1105, 2008.
  • Yu H., Kortylewski M., Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nature Rev. Immunol., 1, 41-51, 2007.
  • Harris T.J., Grosso J.F., Yen H.R., Xin H., Kortylewski M., Albesiano E., Hipkiss E.L., Getnet D., Goldberg M.V., Maris C.H., Housseau F., Yu H., Pardoll D.M., Drake C.G. Cutting Edge: An In Vivo Requirement for STAT3 Signaling in TH17 Development and TH17-Dependent Autoimmunity. J. Immunol. 7, 4313-4317, 2007.
  • Kortylewski M., Jove R., Yu H. Targeting STAT3 affects melanoma on multiple fronts. Cancer Metastasis Rev., 24, 315-327, 2005.
  • Kortylewski M., Kujawski M., Wang T., Wei S., Niu G., Zhang S., Pilon-Thomas S., Kay H., Kerr W.G., Mulé J., Jove R., Pardoll D., Yu H. Inhibiting Stat3 signaling in the hematopoietic system elicits multi-component antitumor immunity. Nature Med., 11, 1314-1321, 2005.
  • Wellbrock C., Weisser C., Hassel J.C., Fischer P., Becker J., Vetter C.S., Behrmann I., Kortylewski M., Heinrich P.C., Schartl M. STAT5 Contributes to Interferon Resistance of Melanoma Cells. Curr. Biol. 15, 1629-1639, 2005.
  • Xu Q., Briggs J., Park S., Niu G., Kortylewski M., Zhang S., Gritsko T., Turkson J., Kay H., Semenza G.L., Cheng J.Q., Jove R., Yu H. Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene, 24, 5552-5560, 2005.
  • Burdelya L., Kujawski M., Niu G., Zhong B., Wang T., Zhang S., Kortylewski M., Shain K., Kay H., Djeu J., Dalton W., Pardoll D., Wei S., Yu H. Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects. J. Immunol., 174, 3925-3931, 2005.
  • Wang T.*, Niu G.*, Kortylewski M.*, Burdelya L.*, Shain K., Zhang S., Bhattacharya R., Gabrilovich D., Heller R., Coppola D., Dalton W., Jove R., Pardoll D., Yu H. Regulation of the innate and adaptive immune responses by Stat3 signaling in tumor cells. Nature Med., 10, 48-54, 2004. *equally contributing authors.
  • Kortylewski M., Kaufmann M.-E., Bosserhoff A., Heinrich P.C. Behrmann I. IFN-mediated growth regulation of melanoma cells: involvement of STAT1-dependent and –independent signals. J. Invest. Dermatol., 122, 414-422, 2004.
  • Kortylewski M., Feld F., Krüger K.-D., Bahrenberg G., Roth R.A., Joost H. G., Heinrich P.C., Behrmann I., Barthel A. Akt modulates STAT3-mediated gene expression through a FKHR (FOXO1a)-dependent mechanism. J. Biol. Chem., 278, 5242-5249, 2003.
  • Böhm M., Schulte U., Funk J.O., Raghunath M., Behrmann I., Kortylewski M., Heinrich P.C., Luger T.A., and Schwarz T. IL-6 resistant melanoma cells exhibit reduced activation of STAT3 and lack of inhibition of cyclin E-associated kinase activity. J. Invest. Dermatol., 117, 132-140, 2001.
  • Kortylewski M., Heinrich P.C., Kauffmann M.-E., Böhm M., Mackiewicz A., Behrmann I. Mitogen-activated protein kinases control p27/Kip1 expression and growth of human melanoma cells. Biochem J., 357, 297-303, 2001.
  • Thiel S., Sommer U., Kortylewski M., Haan C., Behrmann I., Heinrich P.C. and Graeve L. Termination of IL-6-induced STAT activation is independent of receptor internalization but requires de novo protein synthesis. FEBS Lett., 470, 15-19, 2000.
  • Haan S., Kortylewski M., Behrmann I., Müller-Esterl W., Heinrich P.C. and Schaper F. Cytoplasmic STAT proteins associate prior to activation. Biochem J., 345, 417-421, 2000.
  • Kortylewski M., Heinrich P.C., Mackiewicz A., Schniertshauer U., Klingmüller U., Nakajima K., Hirano T., Horn F. and Behrmann I. Interleukin-6 and oncostatin M-induced growth inhibition of human A375 melanoma cells is STAT-dependent and involves upregulation of the cyclin-dependent kinase inhibitor p27/Kip1. Oncogene, 18, 3742-3753, 1999.


  • City of Hope - Main Campus (Duarte)
    1500 East Duarte Road
    Duarte, CA 91010